Heparin Sodium

(Heparin)

ApprovedSmall molecule

Heparin is a blood thinner used to prevent and treat blood clots, and to reduce the risk of stroke or heart attack in patients at high risk.[2] Heparin Sodium is currently approved and in use across 62 indications[4].[1]

Heparin Sodium is one of 1077 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

146

Total Trials

Active Trials

1,076

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceActive, not recruiting

ThrombophlebitisApproved

Coronary Artery DiseaseApproved

Metabolic SyndromeActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Fetal Growth RestrictionApproved

Venous ThromboembolismApproved

Varicose VeinsActive, not recruiting

Thrombotic DiseaseApproved

IschemiaActive, not recruiting

Insulin ResistancePreclinical

Active, not recruiting

ThrombophlebitisApproved

Approved

Coronary Artery DiseaseApproved

Approved

Metabolic SyndromePreclinical

Active, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Fetal Growth RestrictionApproved

Approved

Venous ThromboembolismApproved

Approved

Varicose VeinsApproved

Active, not recruiting

Thrombotic DiseaseApproved

Approved

IschemiaApproved

Active, not recruiting

Showing 10 of 60 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Heparin Sodium

BBaxter Healthcare Corporation

Approved

4 2

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 3

Rayaldee

OOrganon and Co

Preclinical

1 4

Statins

Sanofi

Preclinical

1 5

Olokizumab

UCB

Preclinical

1 6

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 7

Blood Taken

HHospices Civils de Lyon

Preclinical

1 8

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

Pfizer-COVID-19 Vaccine

Moderna

Preclinical

1 10

Other Tkis

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Not yet recruiting

MPA

NCT06112262

Q4 2026

Phase 3Recruiting

Catheter

NCT04374799

N/AActive, not recruiting

Metabolic Syndrome

NCT02653092

Q1 2027

Phase 3Recruiting

Bloodstream Infection

NCT06822426

Phase 2/3Recruiting

Acute Respiratory Failure

NCT04273607

N/ARecruiting

Lipoprotein Lipase Deficiency

NCT04227678

Clinical

Trials by Indication[1]

Anticoagulation6 trials

Reduced Anticoagulation Targets in ECLS (RATE)

Completed·UUniversity Medical Center Groningen·Phase 3·NCT04536272·330 enrolled

Randomized Anticoagulation Trial in Opcab (RATIO)

Unknown status·AAzienda Ospedaliera di Lecco·Phase 4·NCT02812355·900 enrolled

Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure

Completed·UUniversity Hospital Ostrava··NCT06038682·100 enrolled

Show 3 more trials

Anticoagulation in Blunt Cerebrovascular Injuries

Withdrawn·—·N/A·NCT00494156

A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

Recruiting·—·N/A·NCT06676085·60 enrolled

TEG Anticoagulation Monitoring During ECMO

Completed·PPoliclinico Hospital·Phase 1·NCT02271126·42 enrolled

COVID-194 trials

Nebulized Heparin for the Treatment of COVID-19

Completed·FFrederick Health·Phase 4·NCT04723563·50 enrolled

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

Completed·AARCA Biopharma, Inc.·Phase 2/3·NCT04655586·160 enrolled

Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.

Completed·UUniversity Hospital, Ghent··NCT05224388·813 enrolled

Show 1 more trial

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Terminated·FFrederick Health·Phase 4·NCT04397510·13 enrolled

Venous thrombosis4 trials

Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)··NCT00005684

Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients

Withdrawn·LLisa Louwers·N/A·NCT01325779

Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis

Terminated·JJan Stam, MD, PhD·Phase 2/3·NCT01204333·67 enrolled

Show 1 more trial

Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies

Unknown status·—·N/A·NCT03483207·30 enrolled

Complication4 trials

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

Completed·UUniversity of Manitoba·Phase 2/3·NCT04372589·1,200 enrolled

Comparison of Effectiveness and Complications of Catheter Lock Solutions in Non-tunneled Hemodialysis Catheters

Completed·—·N/A·NCT04772209·441 enrolled

Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure

Terminated·UUniversity Hospital, Montpellier·Phase 4·NCT01823393·94 enrolled

Show 1 more trial

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Recruiting·UUniversity of Manitoba·Phase 3·NCT05848713·4,000 enrolled

Safety and Efficacy3 trials

Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMI

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT04475835·100 enrolled

Safety and Efficacy of Low-dose hEparinization in Cerebral Angiography sTudy

Completed·XXuanwu Hospital, Beijing·Phase 4·NCT06365398·180 enrolled

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Recruiting·VVaneltix Pharma, Inc.·Phase 2·NCT05737121·120 enrolled

88 more indications

Surgery3 trials

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

Completed·—··NCT00237328·1,015 enrolled

Optimized Heparin Regimen in Vascular Surgery

Completed·—·N/A·NCT02477072·32 enrolled

Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

Completed·WWashington University School of Medicine·Phase 2/3·NCT00329433·120 enrolled

Bloodstream Infection3 trials

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

Completed·CCorMedix·Phase 3·NCT02651428·806 enrolled

Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 4·NCT02515201·20 enrolled

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

Recruiting·CCorMedix·Phase 3·NCT06822426·200 enrolled

Treatment3 trials

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

Unknown status·UUniversity of Wisconsin, Madison·Phase 1·NCT02435732·72 enrolled

Treatment for Blood Clots in the Veins of the Legs

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00001713·20 enrolled

The Effect of Heparin in Treatment IVF-ET Failure

Completed·—·Phase 4·NCT01214772·86 enrolled

Acute Coronary Syndrome3 trials

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

Completed· Novartis logo

Novartis·Phase 3·NCT01087723·2,198 enrolled

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

Completed·RRegado Biosciences, Inc.·Phase 2·NCT00932100·640 enrolled

Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00373451·1,721 enrolled

Acute Myocardial Infarction3 trials

Bivalirudin in Acute Myocardial Infarction

Unknown status·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 3·NCT02897037·380 enrolled

BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.

Completed·SShenyang Northern Hospital·Phase 4·NCT01696110·2,194 enrolled

Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02181985·5,989 enrolled

Cardiopulmonary Bypass3 trials

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

Completed·MMayo Clinic·Phase 3·NCT00587444·270 enrolled

Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery

Recruiting·LLaval University·N/A·NCT03302195·410 enrolled

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

Completed· Novartis logo

Novartis·Phase 3·NCT00079586·150 enrolled

Percutaneous Coronary Intervention3 trials

Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.

Unknown status·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT04046029·240 enrolled

Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention

Terminated·SStony Brook University·Phase 4·NCT01464671·260 enrolled

A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.

Completed·CCentocor, Inc.·Phase 3·NCT00269880·2,792 enrolled

Infusion3 trials

Bivalirudin Infusion for Ventricular Infarction Limitation

Terminated· Novartis logo

Novartis·Phase 3·NCT02565147·78 enrolled

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

Completed·SStanford University·Phase 1·NCT02687256·24 enrolled

Assessment of the Anti-inflammatory Effect of Heparin Infusion Versus Subcutaneous Injection in Septic Patients

Completed·—·Phase 2·NCT04313790·40 enrolled

Venous Thromboembolism3 trials

Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

Terminated·—·Phase 3·NCT02664155·203 enrolled

Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

Withdrawn·NNYU Langone Health·N/A·NCT02707263

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Terminated·JJohns Hopkins University·Phase 4·NCT03006562·501 enrolled

Islet Transplantation3 trials

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00789308·24 enrolled

Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation

Terminated·TTikoMed AB·Phase 2·NCT03867851·7 enrolled

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

No longer available·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT01049633

Antithrombotic2 trials

Antithrombotic Regimens and Outcome

Completed·—·Phase 4·NCT00448461·850 enrolled

Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin

Completed·—·N/A·NCT01855516·83 enrolled

Pregnancy2 trials

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Unknown status·SShanghai First Maternity and Infant Hospital·Phase 4·NCT02990403·500 enrolled

Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin

Unknown status·—·Phase 3·NCT02144064·200 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00311753·342 enrolled

A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab

Completed·CCentocor, Inc.·Phase 3·NCT00271401·2,399 enrolled

Myocardial Infarction2 trials

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00976092·548 enrolled

Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction

Unknown status·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT03882775·240 enrolled

Flushing2 trials

Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients

Terminated·—·Phase 3·NCT01343680·2 enrolled

Effects of Different Concentrations of Pressurized-heparin Flushing Fluid on Coagulation and Platelet Function Monitored by the Sonoclot Analyzer

Completed·YYangzhou University·N/A·NCT04355273·60 enrolled

MPA2 trials

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration

Unknown status·BBlau Farmaceutica S.A.·Phase 1·NCT05788913·68 enrolled

Comparison Between Haparin and Herodin in HD

Not yet recruiting·BBasma Rabiey·Phase 1·NCT06112262·98 enrolled

ESS2 trials

Prostacyclin's Effect on Platelet Responsiveness

Completed·—·Phase 4·NCT00890214·23 enrolled

Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment

Completed·UUniversity of Colorado, Denver··NCT02656095·12 enrolled

Intravenous2 trials

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Unknown status·AAzidus Brasil·Phase 1·NCT01651923·60 enrolled

Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery

Completed·UUniversity of Colorado, Denver·N/A·NCT01608906·152 enrolled

Effectiveness2 trials

Comparative Effectiveness of 30%TSC and Heparin Lock Solution in Hemodialysis Catheters

Completed·—·Phase 4·NCT02563041·179 enrolled

Sodic Heparin Effectiveness of the Treatment of Burns

Withdrawn·AAzidus Brasil·Phase 2/3·NCT00701623

Prophylaxis2 trials

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

Completed·MMedical College of Wisconsin·Phase 2·NCT03672006·20 enrolled

Timing of VTE Prophylaxis in TBI

Withdrawn·LLoyola University·Phase 4·NCT03081169

Pulmonary Embolism2 trials

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

Completed· Sanofi logo

Sanofi·Phase 3·NCT00062803

Percutaneous Embolectomy, Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY II)

Recruiting·JJesper Kjaergaard·Phase 3·NCT06453876·210 enrolled

Percutaneous Coronary Intervention (PCI)2 trials

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Withdrawn·SSchering-Plough·Phase 2·NCT00060554·300 enrolled

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 2·NCT00508924·140 enrolled

Dialysis Patients2 trials

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

Completed·RRockwell Medical Technologies, Inc.·Phase 1/2·NCT04042324·12 enrolled

Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT00885300·100 enrolled

Acute Respiratory Failure2 trials

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Terminated·BBrittany Bissell·Phase 2·NCT04842292·2 enrolled

Anticoagulation-free VV ECMO for Acute Respiratory Failure

Recruiting·DDamian Ratano·Phase 2/3·NCT04273607·40 enrolled

Catheter2 trials

Heparin vs Placebo for Cardiac Catheterization

Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT04374799·1,623 enrolled

Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates

Withdrawn·TThe University of Texas Health Science Center at San Antonio·N/A·NCT00879957

Resistance1 trial

Heparin Resistance: Predictors and Outcomes

Completed·YYonsei University·N/A·NCT01044888·199 enrolled

Cardiac Surgery1 trial

Understanding "Heparin Resistance" in Cardiac Surgery

Completed·MMassachusetts General Hospital·Phase 1·NCT01598883·504 enrolled

Hereditary Angioedema1 trial

Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations

Completed·UUniversity of Iowa·N/A·NCT00004694·24 enrolled

Oxidative Stress1 trial

Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes (HECICS)

Completed·ZZiekenhuis Oost-Limburg·N/A·NCT02674906·75 enrolled

Cerebral Venous Sinus Thrombosis1 trial

Endovascular Treatment or Standard Medical Care for Cerebral Venous Sinus Thrombosis(ESCORT)

Recruiting·—·N/A·NCT06583889·224 enrolled

Arteriovenous Fistula1 trial

Effects of Heparin on Arteriovenous Fistula Patency

Completed·FFatemeh Hoseinzadegan·Phase 4·NCT02493504·150 enrolled

Thrombosis1 trial

Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coronary Angiography

Completed·PPrince Sultan Cardiac Center, Adult Cardiology Department.·Phase 3·NCT01260519·304 enrolled

Function1 trial

Effect of Increased Free Fatty Acids on Leptin Function

Completed·—·N/A·NCT01520454·26 enrolled

Kidney Transplant1 trial

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00790439

Insulin resistance1 trial

Study of the Relationship Between Body Composition, Insulin Resistance and HDL Levels

Terminated·UUniversity of California, Davis··NCT02755818·50 enrolled

Portal vein thrombosis1 trial

TIPS or Anticoagulation in Portal Vein Thrombosis

Withdrawn·IInsel Gruppe AG, University Hospital Bern·Phase 3·NCT03422419

Metabolic Syndrome1 trial

Reprometabolic Syndrome Mediates Subfertility in Obesity

Active, not recruiting·UUniversity of Colorado, Denver·N/A·NCT02653092·84 enrolled

Lower Urinary Tract Symptom1 trial

Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy

Unknown status·TThe Christ Hospital·Phase 2·NCT03633994·104 enrolled

Miscarriage1 trial

Aspirin, Heparin and Miscarriage

Unknown status·UUniversity of Khartoum·Phase 4·NCT01917799·150 enrolled

Aneurysm1 trial

Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms

Unknown status·—·Phase 3·NCT04532333·236 enrolled

Septic Shock1 trial

Safety of Heparin in Patients With Septic Shock

Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT01234285

Pneumonia1 trial

Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia

Withdrawn·DD'Or Institute for Research and Education·Phase 3·NCT04485429

Deep Vein Thrombosis1 trial

Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis

Completed· LEO Pharma logo

LEO Pharma·Phase 4·NCT00277394·541 enrolled

Hemostasis1 trial

Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial

Completed·—·N/A·NCT06549842·451 enrolled

Ischemic stroke1 trial

Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke

Unknown status·UUniversity Hospital, Martin·Phase 4·NCT01862978·150 enrolled

Pediatric Patients1 trial

Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT03894904·100 enrolled

Exercise1 trial

Coronary Arteriogenetic Heparinized Exercise

Completed·CClinical Centre of Serbia·N/A·NCT03350737·32 enrolled

Completed·—·Phase 3·NCT05886998·88 enrolled

Stroke1 trial

Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke

Unknown status·SShiraz University of Medical Sciences·Phase 2·NCT02159287·80 enrolled

Coronary Microvascular Dysfunction1 trial

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

Active, not recruiting·NNYU Langone Health·N/A·NCT03537586·206 enrolled

Thromboembolism1 trial

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19

Completed·—·Phase 4·NCT04367831·94 enrolled

Intrauterine Adhesions1 trial

Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy

Recruiting·NNadezhda Women's Health Hospital·N/A·NCT05257213·100 enrolled

Ischemia1 trial

Predictive Factors of Intestinal Infraction in Acute Mesenteric Ischemia

Completed·MMansoura University·Phase 4·NCT02645240·97 enrolled

Renal Replacement Therapy1 trial

Investigating Different Anticoagulants for Renal Replacement Therapy

Completed·UUniversity Hospital Muenster·Phase 4·NCT02669589·638 enrolled

PCAB1 trial

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

Completed· Novartis logo

Novartis·Phase 3·NCT00073593·150 enrolled

Heart Disease1 trial

Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI

Unknown status·—·Phase 4·NCT02787317·1,770 enrolled

Homeostasis1 trial

Racial Differences in Vagal Control of Glucose Homeostasis

Completed·VVanderbilt University Medical Center·Phase 1/2·NCT02365285·23 enrolled

Catheter-Related Infections1 trial

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Withdrawn·MM.D. Anderson Cancer Center·N/A·NCT00378781

Myocardial Ischemia1 trial

Thrombolysis in Myocardial Ischemia Trial (TIMI III)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000472

Type 1 Diabetes Mellitus1 trial

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 1·NCT02910518·44 enrolled

Interstitial Cystitis1 trial

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Terminated·UUrigen·Phase 2·NCT02591199·91 enrolled

Chronic Total Occlusion1 trial

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Withdrawn·BBoston Scientific Corporation··NCT04059536

Enoxaparin1 trial

Heparin or Enoxaparin in Patients With Cancer

Completed·NNorthwestern University··NCT00004875·6 enrolled

Bleeding1 trial

EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding

Unknown status·LLaval University·Phase 4·NCT01084993·2,000 enrolled

Antiplatelet Therapy1 trial

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

Completed·UUppsala University·Phase 4·NCT02311231·6,012 enrolled

Atrial Appendage1 trial

Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT04195997·100 enrolled

STEMI1 trial

Bivalirudin in Late PCI for Oatients With STEMI

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 4·NCT04185077·1,200 enrolled

Anticoagulant1 trial

A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05178550·12 enrolled

Mechanical Ventilation in Neonates1 trial

Impact of Heparin on the Need for Mechanical Ventilation in Neonates

Unknown status·UUniversity Medicine Greifswald·Phase 4·NCT00196469·270 enrolled

Thoracic Surgery1 trial

Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery

Unknown status·WWest China Hospital·Phase 1/2·NCT02940444·2,000 enrolled

Occlusion1 trial

Radial Artery Occlusion After Endovascular Procedure

Unknown status·AAzienda Sanitaria ULSS 13 Dolo, Mirano··NCT02762344·2,168 enrolled

MACE1 trial

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Unknown status·AAzidus Brasil·Phase 1·NCT01652638·44 enrolled

OIC1 trial

HEROIC (Heparin Requirement in Counterpulsation)

Terminated·CCorewell Health East·Phase 2·NCT00445211·46 enrolled

Spontaneous Abortion1 trial

Diagnosis and Treatment Strategy of Recurrent Spontaneous Abortion Associated With Thrombophilla

Unknown status·SShanghai First Maternity and Infant Hospital·Phase 4·NCT02986594·600 enrolled

Sepsis1 trial

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06381661·2,000 enrolled

Colorectal Surgery1 trial

Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery

Completed·—·Phase 3·NCT01976988·410 enrolled

Intravenous Administration1 trial

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration

Unknown status·BBlau Farmaceutica S.A.·Phase 1·NCT05788900·68 enrolled

Randomized1 trial

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

Unknown status·AAsh Access Technology·Phase 3·NCT00628680·415 enrolled

Lipoprotein Lipase Deficiency1 trial

Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency

Recruiting·UUniversité de Sherbrooke·N/A·NCT04227678·16 enrolled

Cardiac Failure1 trial

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

Recruiting·SStanford University·Phase 2·NCT06080074·50 enrolled

Interaction1 trial

Palifermin DDI (Drug Drug Interaction)

Completed·SSwedish Orphan Biovitrum·Phase 1·NCT00361348·45 enrolled

Hemodynamic1 trial

Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters

Completed·MMedical University of Vienna·N/A·NCT00431665·9 enrolled

Age1 trial

Comparison of Two Dosages of Heparin Before Extracorporeal Circulation

Completed·AAstes·Phase 4·NCT03752437·150 enrolled

Burn Wound1 trial

Heparin for the Treatment of Burn Wound Pain

Unknown status·KKing Edward Medical University·N/A·NCT02497326·36 enrolled

Anaphylactic Reaction1 trial

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

Withdrawn·UUniversity of Missouri, Kansas City·N/A·NCT00657228

Unspecified3 trials

Verapamil vs Heparin in Transradial Procedures

Completed·UUniversity Hospital of Ferrara·Phase 4·NCT02454491·418 enrolled

Study to Characterize the Effect of Heparin on Palifermin Activity

Completed·SSwedish Orphan Biovitrum·Phase 1·NCT01163097·44 enrolled

Heparin Solution and INTEM/HEPTEM Analysis

Completed·SSeoul National University Bundang Hospital··NCT01522846·25 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

CALCIPARINE

NDA NDA018237

Jan 1, 1982

HEPARIN SODIUM

NDA NDA004570

Jan 1, 1982

LIPO-HEPIN

NDA NDA017027

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017780

Jan 1, 1982

HEPARIN LOCK FLUSH

NDA NDA005264

Jan 1, 1982

HEPARIN LOCK FLUSH

NDA NDA017346

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017033

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017979

Jan 1, 1982

HEPARIN SODIUM

NDA NDA000552

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017130

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017540

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017064

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017486

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017029

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017651

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017007

Jan 1, 1982

HEPARIN SODIUM

NDA NDA017037

Jan 1, 1982

HEPARIN SODIUM

NDA NDA005521

Apr 28, 1982

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

NDA NDA018609

Dec 31, 1984

HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA019130

Jan 30, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

NDA NDA018911

Mar 27, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA019339

Mar 29, 1985

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

NDA NDA019135

Mar 29, 1985

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA019134

Mar 29, 1985

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

NDA NDA019042

Jul 9, 1985

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA018814

Mar 4, 1988

SODIUM HEPARIN

NDA NDA017036

Jan 25, 1989

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA019805

Jun 23, 1989

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

NDA NDA018916

Jul 20, 1992

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

NDA NDA019953

Jul 20, 1992

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

NDA NDA019802

Jul 20, 1992

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA019952

Jul 21, 2011

HEPARIN SODIUM

NDA NDA201370

Sources

References

[1]
ClinicalTrials.gov — 146 trial records for Heparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Heparin Sodium drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Heparin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Heparin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA201370). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Baxter Healthcare Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Antithrombin-III Activator[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: BBaxter Healthcare Corporation

Heparin Sodium

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Anticoagulation6 trials

COVID-194 trials

Venous thrombosis4 trials

Complication4 trials

Safety and Efficacy3 trials

Surgery3 trials

Bloodstream Infection3 trials

Treatment3 trials

Acute Coronary Syndrome3 trials

Acute Myocardial Infarction3 trials

Cardiopulmonary Bypass3 trials

Percutaneous Coronary Intervention3 trials

Infusion3 trials

Venous Thromboembolism3 trials

Islet Transplantation3 trials

Antithrombotic2 trials

Pregnancy2 trials

Efficacy and Safety2 trials

Myocardial Infarction2 trials

Flushing2 trials

MPA2 trials

ESS2 trials

Intravenous2 trials

Effectiveness2 trials

Prophylaxis2 trials

Pulmonary Embolism2 trials

Percutaneous Coronary Intervention (PCI)2 trials

Dialysis Patients2 trials

Acute Respiratory Failure2 trials

Catheter2 trials

Resistance1 trial

Cardiac Surgery1 trial

Hereditary Angioedema1 trial

Oxidative Stress1 trial

Cerebral Venous Sinus Thrombosis1 trial

Arteriovenous Fistula1 trial

Thrombosis1 trial

Function1 trial

Kidney Transplant1 trial

Insulin resistance1 trial

Portal vein thrombosis1 trial

Metabolic Syndrome1 trial

Lower Urinary Tract Symptom1 trial

Miscarriage1 trial

Aneurysm1 trial

Septic Shock1 trial

Pneumonia1 trial

Deep Vein Thrombosis1 trial

Hemostasis1 trial

Ischemic stroke1 trial

Pediatric Patients1 trial

Exercise1 trial

Injury1 trial

Hemodialysis1 trial

Acute Lung Injury1 trial

Stroke1 trial

Coronary Microvascular Dysfunction1 trial

Thromboembolism1 trial

Intrauterine Adhesions1 trial

Ischemia1 trial

Renal Replacement Therapy1 trial

PCAB1 trial

Heart Disease1 trial

Homeostasis1 trial

Catheter-Related Infections1 trial

Myocardial Ischemia1 trial

Type 1 Diabetes Mellitus1 trial

Interstitial Cystitis1 trial

Chronic Total Occlusion1 trial

Enoxaparin1 trial

Bleeding1 trial

Antiplatelet Therapy1 trial